Tags: Lilly | earnings | drugs | profit

Lilly Beats Wall Street Expectations, Helped by Cost Cuts

Wednesday, 23 Oct 2013 07:04 AM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
Eli Lilly and Co. on Wednesday reported better-than-expected quarterly earnings, helped by cost cuts and a big price increase for Cymbalta, its top-selling antidepressant that begins facing generic competition in December.

The Indianapolis drugmaker earned $1.20 billion, or $1.11 per share, in the third quarter. That compared with $1.33 billion, or $1.18 per share, in the year-earlier period, when it took special charges related to a partnership agreement.

Excluding special items, Bristol-Myers earned $1.11 per share. Analysts, on average, expected $1.04, according to Thomson Reuters I/B/E/S.

Company sales rose 6 percent to $5.78 billion, slightly above Wall Street expectations of $5.76 billion, with most of the revenue growth coming from price increases on its medicines. Global company sales would have risen 8 percent, if not for the weaker dollar, which lowers the value of sales in overseas markets.

The company squeezed 11 percent growth for its anti-depressant Cymbalta by raising prices, bring its sales to $1.38 billion. But the number of prescriptions filled for Lilly's flagship product declined during the quarter.

Sales of lung cancer drug Alimta rose 7 percent to $691 million, while anti-impotence treatment Cialis jumped 9 percent to $527 million. Sales of osteoporosis drug Evista, which loses patent protection early next year, were up 3 percent to $256 million.

Lilly's marketing, selling and administrative expenses shrank by 6 percent in the quarter.

Lilly said it expects full-year earnings of $4.10 to $4.15 per share, excluding special items. It had forecast $4.05 to $4.15 per share.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web

Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 

You May Also Like
Around the Web

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved